Key Points
- Edwards VP Donald Bobo Jr. sold 11,340 shares on Jan. 6 at an average price of $85.66 for about $971,384, trimming his stake to 31,870 shares (a 26.24% decrease).
- Edwards beat expectations in its most recent quarter with $0.67 EPS and $1.55B revenue, and set FY2025 guidance of 2.560–2.620 EPS (analysts average ~2.45 EPS).
- The stock has a market cap of roughly $49.8B and a PE of 37.0, trades near its 52‑week high, and carries a consensus "Moderate Buy" rating with a $94.05 price target.
Edwards Lifesciences Corporation (NYSE:EW - Get Free Report) VP Donald Bobo, Jr. sold 11,340 shares of Edwards Lifesciences stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $85.66, for a total transaction of $971,384.40. Following the sale, the vice president owned 31,870 shares in the company, valued at approximately $2,729,984.20. This represents a 26.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Edwards Lifesciences Stock Performance
Shares of EW opened at $85.86 on Wednesday. The firm has a market capitalization of $49.82 billion, a PE ratio of 37.01, a P/E/G ratio of 3.42 and a beta of 0.95. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06. The firm has a 50-day moving average price of $84.94 and a 200 day moving average price of $80.19. Edwards Lifesciences Corporation has a 52-week low of $65.94 and a 52-week high of $87.89.
Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, topping analysts' consensus estimates of $0.59 by $0.08. The company had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. Edwards Lifesciences's revenue was up 14.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. On average, sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities analysts have recently issued reports on the company. BTIG Research reiterated a "buy" rating and set a $103.00 price target (up from $100.00) on shares of Edwards Lifesciences in a research report on Thursday, December 4th. Truist Financial set a $92.00 target price on Edwards Lifesciences and gave the stock a "hold" rating in a report on Friday, December 5th. Mizuho upped their price target on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the company an "outperform" rating in a report on Friday, October 31st. Royal Bank Of Canada lifted their price objective on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the stock an "outperform" rating in a research note on Friday, December 5th. Finally, UBS Group set a $92.00 target price on shares of Edwards Lifesciences in a research note on Friday, December 5th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $94.05.
Get Our Latest Research Report on EW
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Level Four Advisory Services LLC boosted its stake in Edwards Lifesciences by 3.7% in the 3rd quarter. Level Four Advisory Services LLC now owns 3,301 shares of the medical research company's stock worth $257,000 after purchasing an additional 119 shares during the period. Colonial Trust Co SC lifted its holdings in shares of Edwards Lifesciences by 0.4% in the third quarter. Colonial Trust Co SC now owns 32,196 shares of the medical research company's stock valued at $2,504,000 after purchasing an additional 120 shares in the last quarter. Parkside Financial Bank & Trust boosted its position in shares of Edwards Lifesciences by 9.8% in the second quarter. Parkside Financial Bank & Trust now owns 1,455 shares of the medical research company's stock worth $114,000 after buying an additional 130 shares during the period. Prosperity Consulting Group LLC grew its holdings in shares of Edwards Lifesciences by 3.2% during the second quarter. Prosperity Consulting Group LLC now owns 4,304 shares of the medical research company's stock valued at $337,000 after buying an additional 132 shares in the last quarter. Finally, Howard Capital Management Inc. raised its position in Edwards Lifesciences by 3.3% during the third quarter. Howard Capital Management Inc. now owns 4,136 shares of the medical research company's stock valued at $322,000 after buying an additional 132 shares during the period. 79.46% of the stock is owned by hedge funds and other institutional investors.
About Edwards Lifesciences
(
Get Free Report)
Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.
In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
